Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate.

Dean Advantage-
Phototherapy for Skin Conditions, including Home Ultraviolet Light (UVB) MP9057

This policy is specific to the Dean Advantage product.

Covered Service: Yes–when meets criteria below

Prior Authorization Required: Yes–home based units require prior authorization

Additional Information: Dean Health Plan covers the purchase of one system per enrollee per lifetime. The enrollees are responsible for the cost of repairs or replacement lights

Dean Health Plan Medical Policy:

1.0 Phototherapy is the administration of artificial UV light: UVA (320 to 400 nm), UVA1 (340 to 400 nm), broadband UVB (290 to 320 nm), or narrowband UVB (311 to 313 nm). It is usually given in a stand-up cabinet, with lights at a fixed distance around the walls. Phototherapy requires prior authorization through the Quality and Care Management Division and may be considered medically necessary for 1 or more of the following:

1.1 Atopic dermatitis (eczema), as indicated by ALL of the following:
   1.1.1 Clinically severe dermatitis, as indicated by 1 or more of the following:
      1.1.1.1 Greater than 20% total skin involvement; OR
      1.1.1.2 Greater than 10% skin involvement of sensitive areas; OR
      1.1.1.3 Severe complications (e.g. infection)
   1.1.2 Inadequate response to ALL of the following:
      1.1.2.1 Identification and elimination of triggering factors; AND
      1.1.2.2 Standard medical management (e.g., topical steroids, antihistamines, etc.)

1.2 Cutaneous graft versus host disease, and resistance or toxicity to immunosuppressive therapy.

1.3 Mycosis fungoides (cutaneous T-cell lymphoma), as indicated by 1 or more of the following:
   1.3.1 Severe psoriasis with a history of frequent flares; OR
   1.3.2 Stage I disease; OR
Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member’s benefit certificate.

1.3.3 Stage Ila disease.

1.4 Polymorphous light eruption, as indicated by **ALL** of the following:
   1.4.1 Desensitization by gradually increasing exposure to sun in spring has been ineffective; **AND**
   1.4.2 Inadequate response or contraindication to medical management; **AND**
   1.4.3 Prophylactic treatment with sunscreen ineffective; **AND**
   1.4.4 Severe or recurrent disease.

1.5 Pruritis and **1 or more** of the following:
   1.5.1 Chronic renal failure; **OR**
   1.5.2 Cirrhosis; **OR**
   1.5.3 Polycythemia vera.

1.6 Psoriasis, as indicated by **1 or more** of the following:
   1.6.1 Inadequate response to topical therapy; **OR**
   1.6.2 Involved surface area too extensive for treatment with topical therapy; **OR**
   1.6.3 Severe involvement of feet or hands.

2.0 An in-home Ultraviolet B (UVB) light unit **requires** prior authorization through the Quality and Care Management Division and may be considered medically necessary when it has been documented by a Dermatologist that **ALL** of the following are met:

2.1 Improvement has been demonstrated with the use of UV treatments in the physician’s office or clinic; **AND**
   2.1.1 The patient is capable of operating the home phototherapy unit, staying within prescribed periods of exposure, and the unit is expected to be used frequently (e.g., 3 times/week) on a long-term basis; **AND**

2.2 Treatment is expected to be long term (3 months or longer); **AND**

2.3 The member meets **1 or more** of the following:
   2.3.1 The member is unable to attend office-based therapy due to a serious medical or physical condition; **OR**
   2.3.2 Office based therapy has been trialed and helped to control the disease and it is likely that home based therapy will be successful; **OR**
   2.3.3 The member suffers from severe psoriasis with a history of frequent flares which require immediate treatment to control the disease.

3.0 Commercial tanning beds do not qualify as an office trial, and are considered not medically necessary and therefore are not covered.
Coverage of any medical intervention discussed in a Dean Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate.

4.0 Home UVB phototherapy for the treatment of vitiligo is considered experimental and investigational and therefore are not covered.

<table>
<thead>
<tr>
<th>Committee/Source</th>
<th>Date(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Originated:</td>
<td>December 16, 2015</td>
</tr>
<tr>
<td>Medical Director Committee/Quality and Care Management Division</td>
<td></td>
</tr>
<tr>
<td>Revised:</td>
<td>July 20, 2016</td>
</tr>
<tr>
<td>Medical Policy Committee/Quality and Care Management Division</td>
<td></td>
</tr>
<tr>
<td>Medical Policy Committee/Quality and Care Management Division</td>
<td></td>
</tr>
<tr>
<td>Reviewed:</td>
<td>March 15, 2016</td>
</tr>
<tr>
<td>Medical Policy Committee/Quality and Care Management Division</td>
<td></td>
</tr>
<tr>
<td>Medical Policy Committee/Quality and Care Management Division</td>
<td></td>
</tr>
<tr>
<td>Medical Policy Committee/Quality and Care Management Division</td>
<td></td>
</tr>
<tr>
<td>Published/Effective:</td>
<td>08/01/2017</td>
</tr>
</tbody>
</table>